Amundi Has $446,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Amundi raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 188.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,568 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,168 shares during the quarter. Amundi’s holdings in Collegium Pharmaceutical were worth $446,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its holdings in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Geode Capital Management LLC increased its position in Collegium Pharmaceutical by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock worth $29,974,000 after buying an additional 5,464 shares during the period. Massachusetts Financial Services Co. MA increased its position in Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after buying an additional 116,327 shares during the period. Charles Schwab Investment Management Inc. increased its position in Collegium Pharmaceutical by 4.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock worth $14,741,000 after buying an additional 16,655 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the period.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $29.93 on Friday. The business’s 50 day simple moving average is $30.75 and its 200 day simple moving average is $32.77. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The stock has a market capitalization of $942.38 million, a PE ratio of 12.90 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. This represents a 0.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,193 shares of company stock worth $3,243,594. Corporate insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.